GOVX — GeoVax Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 832489 ·
Last close
$0.35
Market Cap
$3.14M
52W High
$16.80
52W Low
$0.34
ADV30
951,571
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,442,072 | -4,426,578 | 4,642,757 | 3,143,422 | 2,882,056 |
| Mar 2026 | 0 | — | -5,272,881 | -5,261,921 | 2,982,433 | 1,271,762 | 2,488,663 |
| Dec 2025 | 0 | — | -4,441,756 | -4,418,423 | 6,341,868 | 3,085,741 | 2,516,736 |
| Sep 2025 | 0 | — | -6,373,215 | -6,318,914 | 6,731,255 | 5,008,997 | 1,824,177 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,369,715
Investing CF
$0
Financing CF
$18,419,275
CapEx
$-27,612
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-20.08
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-160,509,351
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-20,452,290
Pretax Income TTM
$-20,425,836
Interest Exp TTM
$0
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-20,470,740
Free Cash Flow
$-10,819,786
Enterprise Value
$591,678
Total Cash
$3,143,422
Total Debt
$323,141
Shares Out
9,093,871
Trailing EPS
$-5.62
Book Value
$0.24
ROE
-891.6%
ROA
-256.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,489,145 | -21,639,047 | -21,464,771 | 6,341,868 | 2,516,736 | 3,825,132 | -21,473,969 |
| Dec 2024 | 3,954,576 | -25,144,280 | -24,992,296 | 8,155,867 | 3,107,332 | 5,048,535 | -24,675,511 |
| Dec 2023 | 0 | -26,742,939 | -25,966,762 | 9,283,219 | 3,519,881 | 5,763,338 | -25,173,639 |
| Dec 2022 | 81,526 | -14,028,564 | -14,021,125 | 31,347,928 | 4,747,894 | 26,600,034 | -19,030,208 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.86
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.17M | $0.05 | — |
| SBFM | Sunshine Biopharma Inc. | $3.17M | $0.82 | — |
| XRTX | XORTX Therapeutics Inc. | $3.11M | $1.71 | — |
| RDHL | RedHill Biopharma Ltd. | $3.07M | $0.51 | — |
| JUNS | JUPITER NEUROSCIENCES, INC. | $3.31M | $2.51 | — |
News headlines (Yahoo Finance, 1h cache)
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
2026-09-21 12:37 · Yahoo
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
2026-09-14 12:37 · Yahoo
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
2026-09-10 12:37 · Yahoo
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
2026-09-09 13:00 · Yahoo
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
2026-08-25 12:37 · Yahoo
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak
2026-08-24 14:43 · Yahoo
GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies
2026-08-24 12:37 · Yahoo
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
2026-08-20 13:00 · Yahoo
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak
2026-08-13 15:00 · Yahoo
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway
2026-08-10 21:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.